De-intensification of basal-bolus therapy by replacing prandial insulin with once-weekly subcutaneous semaglutide in individuals with well-controlled type 2 diabetes: A single-centre, open-label randomised trial (TRANSITION-T2D).

Rodriguez P, Breslaw N, Xiao H, Bena J, Jenkins K, Isaacs D, Zhou K, Griebeler ML, Burguera B, Pantalone KM

Diabetes, obesity & metabolism12 Nov 2024Cited by 5 (Europe PMC)

PMID39532398PMCIDPMC11701190DOI10.1111/dom.16057PepBankPUB-39532398

Read at source PubMedAsk about this study

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: CC BY-NC. Results still quote short attributed sentences.

Results from this study10

10 results from studies that gave the peptide. 10 results from people.

01HumanRandomized controlled trialEfficacy outcome
In adults with well-controlled type 2 diabetes on multiple daily insulin injections, similar proportions kept HbA1c at or below 7.5% at Week 26 with semaglutide (90%) and with continued injections (75%; p = 0.18).
In plain wordsIn adults with well-controlled type 2 diabetes, about the same share kept blood sugar control with semaglutide as with continued insulin injections.
Peptide
Semaglutide
Outcome
No significant changeProportion maintaining HbA1c at or below 7.5% at Week 26
Study
n = 60
Comparator
Multiple daily insulin injections (MDI)
Analysis
Primary
Outcome group
Glycemic control · Metabolic and weight
Studied dose
1.0 mg once weekly · subcutaneous · 26 weeksAs given in this study (human).
Measurements
Proportion with HbA1c <=7.5%
90%
semaglutide
Proportion with HbA1c <=7.5%
75%
MDI
Source sentences
Summary
At Week 26, 90% of semaglutide and 75% of MDI subjects maintained HbA_1c ≤7.5% (≤58 mmol/mol) (p = 0.18).
2 context sentences(design, population, supporting numbers)
Summary · context
This single-centre, randomised, open-label trial enrolled a statistically predetermined sample of 60 adults with HbA1c ≤7.5% (58 mmol/mol) receiving MDI, with a total daily dose (TDD) ≤120 units/day.
Summary · context
Participants were assigned 2:1 to subcutaneous semaglutide 1.0 mg plus insulin degludec, or to continue MDI.
Report a problemFND-3953239801
02HumanRandomized controlled trialEfficacy outcome
In adults with well-controlled type 2 diabetes, HbA1c fell by 0.5% with semaglutide and did not change with continued multiple daily injections (p = 0.009).
In plain wordsIn adults with well-controlled type 2 diabetes, HbA1c fell with semaglutide and stayed the same with continued insulin injections.
Peptide
Semaglutide
Outcome
DecreaseHbA1c change at Week 26
Study
n = 60
Comparator
Multiple daily insulin injections (MDI)
Outcome group
Glycemic control · Metabolic and weight
Studied dose
1.0 mg once weekly · subcutaneous · 26 weeksAs given in this study (human).
Measurements
HbA1c change
−0.5%
semaglutide
Source sentences
Summary
Mean changes (95% CI) in HbA_1c, weight and percentage body weight for semaglutide versus MDI, respectively, were -0.5% (-0.7, -0.3) versus 0.0% (-0.3, 0.3; p = 0.009); -8.9 kg (-9.9, -7.8) versus 1.5 kg (-0.1, 3.1; p < 0.001); and -8.6% (-9.6, -7.6) versus 1.4% (0.0, 2.8; p < 0.001).
2 context sentences(design, population, supporting numbers)
Summary · context
This single-centre, randomised, open-label trial enrolled a statistically predetermined sample of 60 adults with HbA1c ≤7.5% (58 mmol/mol) receiving MDI, with a total daily dose (TDD) ≤120 units/day.
Summary · context
Participants were assigned 2:1 to subcutaneous semaglutide 1.0 mg plus insulin degludec, or to continue MDI.
Report a problemFND-3953239802
03HumanRandomized controlled trialEfficacy outcome
In adults with well-controlled type 2 diabetes, body weight fell by 8.9 kg with semaglutide and rose by 1.5 kg with continued multiple daily injections (p < 0.001).
In plain wordsIn adults with well-controlled type 2 diabetes, weight fell with semaglutide and rose slightly with continued insulin injections.
Peptide
Semaglutide
Outcome
DecreaseBody weight change (kg) at Week 26
Study
n = 60
Comparator
Multiple daily insulin injections (MDI)
Outcome group
Body weight · Metabolic and weight
Studied dose
1.0 mg once weekly · subcutaneous · 26 weeksAs given in this study (human).
Measurements
Body weight change
−8.9 kg
semaglutide
Body weight change
1.5 kg
MDI
Source sentences
Summary
Mean changes (95% CI) in HbA_1c, weight and percentage body weight for semaglutide versus MDI, respectively, were -0.5% (-0.7, -0.3) versus 0.0% (-0.3, 0.3; p = 0.009); -8.9 kg (-9.9, -7.8) versus 1.5 kg (-0.1, 3.1; p < 0.001); and -8.6% (-9.6, -7.6) versus 1.4% (0.0, 2.8; p < 0.001).
2 context sentences(design, population, supporting numbers)
Summary · context
This single-centre, randomised, open-label trial enrolled a statistically predetermined sample of 60 adults with HbA1c ≤7.5% (58 mmol/mol) receiving MDI, with a total daily dose (TDD) ≤120 units/day.
Summary · context
Participants were assigned 2:1 to subcutaneous semaglutide 1.0 mg plus insulin degludec, or to continue MDI.
Report a problemFND-3953239803
04HumanRandomized controlled trialEfficacy outcome
In adults with well-controlled type 2 diabetes, body weight fell by 8.6% with semaglutide and rose by 1.4% with continued multiple daily injections (p < 0.001).
In plain wordsIn adults with well-controlled type 2 diabetes, percent body weight fell with semaglutide and rose slightly with continued insulin injections.
Peptide
Semaglutide
Outcome
DecreasePercentage body weight change at Week 26
Study
n = 60
Comparator
Multiple daily insulin injections (MDI)
Outcome group
Body weight · Metabolic and weight
Studied dose
1.0 mg once weekly · subcutaneous · 26 weeksAs given in this study (human).
Measurements
Body weight change
−8.6%
semaglutide
Body weight change
1.4%
MDI
Source sentences
Summary
Mean changes (95% CI) in HbA_1c, weight and percentage body weight for semaglutide versus MDI, respectively, were -0.5% (-0.7, -0.3) versus 0.0% (-0.3, 0.3; p = 0.009); -8.9 kg (-9.9, -7.8) versus 1.5 kg (-0.1, 3.1; p < 0.001); and -8.6% (-9.6, -7.6) versus 1.4% (0.0, 2.8; p < 0.001).
2 context sentences(design, population, supporting numbers)
Summary · context
This single-centre, randomised, open-label trial enrolled a statistically predetermined sample of 60 adults with HbA1c ≤7.5% (58 mmol/mol) receiving MDI, with a total daily dose (TDD) ≤120 units/day.
Summary · context
Participants were assigned 2:1 to subcutaneous semaglutide 1.0 mg plus insulin degludec, or to continue MDI.
Report a problemFND-3953239804
05HumanRandomized controlled trialEfficacy outcome
In adults with well-controlled type 2 diabetes, total daily insulin dose fell by 56.0% with semaglutide and rose by 6.7% with continued multiple daily injections (p < 0.001).
In plain wordsIn adults with well-controlled type 2 diabetes, daily insulin dose fell with semaglutide and rose slightly with continued insulin injections.
Peptide
Semaglutide
Outcome
DecreaseInsulin total daily dose change
Study
n = 60
Comparator
Multiple daily insulin injections (MDI)
Outcome group
Glycemic control · Metabolic and weight
Studied dose
1.0 mg once weekly · subcutaneous · 26 weeksAs given in this study (human).
Measurements
Insulin TDD change
−56%
semaglutide
Insulin TDD change
6.7%
MDI
Source sentences
Summary
Insulin TDD decreased 56.0% (-62.3, -49.7) with semaglutide and increased 6.7% (-2.5, 16.0) with MDI (p < 0.001).
2 context sentences(design, population, supporting numbers)
Summary · context
This single-centre, randomised, open-label trial enrolled a statistically predetermined sample of 60 adults with HbA1c ≤7.5% (58 mmol/mol) receiving MDI, with a total daily dose (TDD) ≤120 units/day.
Summary · context
Participants were assigned 2:1 to subcutaneous semaglutide 1.0 mg plus insulin degludec, or to continue MDI.
Report a problemFND-3953239805
06HumanRandomized controlled trialEfficacy outcome
In adults with well-controlled type 2 diabetes, treatment satisfaction scores trended higher with semaglutide than with continued multiple daily injections; no significance was reported.
In plain wordsIn adults with well-controlled type 2 diabetes, satisfaction scores trended higher with semaglutide than with continued insulin injections.
Peptide
Semaglutide
Outcome
No significant changeTreatment satisfaction score
Study
n = 60
Comparator
Multiple daily insulin injections (MDI)
Outcome group
Quality of life · Metabolic and weight
Studied dose
1.0 mg once weekly · subcutaneous · 26 weeksAs given in this study (human).
Source sentences
Summary
Participant treatment satisfaction scores trended higher with semaglutide.
2 context sentences(design, population, supporting numbers)
Summary · context
This single-centre, randomised, open-label trial enrolled a statistically predetermined sample of 60 adults with HbA1c ≤7.5% (58 mmol/mol) receiving MDI, with a total daily dose (TDD) ≤120 units/day.
Summary · context
Participants were assigned 2:1 to subcutaneous semaglutide 1.0 mg plus insulin degludec, or to continue MDI.
Report a problemFND-3953239809
07HumanRandomized controlled trialSafety outcome
In adults with well-controlled type 2 diabetes, hypoglycaemia frequency was similar with semaglutide and with continued multiple daily injections.
In plain wordsIn adults with well-controlled type 2 diabetes, low blood sugar happened about as often with semaglutide as with continued insulin injections.
Peptide
Semaglutide
Outcome
No significant changeHypoglycaemia frequency
Study
n = 60
Comparator
Multiple daily insulin injections (MDI)
Outcome group
Adverse events · Metabolic and weight
Studied dose
1.0 mg once weekly · subcutaneous · 26 weeksAs given in this study (human).
Source sentences
Summary
Hypoglycaemia frequency was similar between groups.
2 context sentences(design, population, supporting numbers)
Summary · context
This single-centre, randomised, open-label trial enrolled a statistically predetermined sample of 60 adults with HbA1c ≤7.5% (58 mmol/mol) receiving MDI, with a total daily dose (TDD) ≤120 units/day.
Summary · context
Participants were assigned 2:1 to subcutaneous semaglutide 1.0 mg plus insulin degludec, or to continue MDI.
Report a problemFND-3953239810
08HumanRandomized controlled trialEfficacy outcome
Among adults with well-controlled type 2 diabetes given semaglutide, 58% reduced their total daily insulin dose by more than 50%.
In plain wordsAmong adults with well-controlled type 2 diabetes given semaglutide, 58% cut their daily insulin dose by more than half.
Peptide
Semaglutide
Outcome
Not applicableProportion with insulin total daily dose reduced by more than 50%
Study
n: not reported in source
Outcome group
Glycemic control · Metabolic and weight
Studied dose
1.0 mg once weekly · subcutaneous · 26 weeksAs given in this study (human).
Measurements
Proportion with insulin TDD reduction >50%
58%
semaglutide
Source sentences
Summary
Among semaglutide subjects, 58% reduced insulin TDD > 50%, 97.5% stopped prandial insulin and 45% lost >10% body weight.
2 context sentences(design, population, supporting numbers)
Summary · context
This single-centre, randomised, open-label trial enrolled a statistically predetermined sample of 60 adults with HbA1c ≤7.5% (58 mmol/mol) receiving MDI, with a total daily dose (TDD) ≤120 units/day.
Summary · context
Participants were assigned 2:1 to subcutaneous semaglutide 1.0 mg plus insulin degludec, or to continue MDI.
Report a problemFND-3953239806
09HumanRandomized controlled trialEfficacy outcome
Among adults with well-controlled type 2 diabetes given semaglutide, 97.5% stopped prandial insulin.
In plain wordsAmong adults with well-controlled type 2 diabetes given semaglutide, almost all (97.5%) stopped mealtime insulin.
Peptide
Semaglutide
Outcome
Not applicableProportion who stopped prandial insulin
Study
n: not reported in source
Outcome group
Glycemic control · Metabolic and weight
Studied dose
1.0 mg once weekly · subcutaneous · 26 weeksAs given in this study (human).
Measurements
Proportion who stopped prandial insulin
97.5%
semaglutide
Source sentences
Summary
97.5% stopped prandial insulin and 45% lost >10% body weight.
2 context sentences(design, population, supporting numbers)
Summary · context
This single-centre, randomised, open-label trial enrolled a statistically predetermined sample of 60 adults with HbA1c ≤7.5% (58 mmol/mol) receiving MDI, with a total daily dose (TDD) ≤120 units/day.
Summary · context
Participants were assigned 2:1 to subcutaneous semaglutide 1.0 mg plus insulin degludec, or to continue MDI.
Report a problemFND-3953239807
10HumanRandomized controlled trialEfficacy outcome
Among adults with well-controlled type 2 diabetes given semaglutide, 45% lost more than 10% of body weight.
In plain wordsAmong adults with well-controlled type 2 diabetes given semaglutide, 45% lost more than a tenth of their body weight.
Peptide
Semaglutide
Outcome
Not applicableProportion losing more than 10% body weight
Study
n: not reported in source
Outcome group
Body weight · Metabolic and weight
Studied dose
1.0 mg once weekly · subcutaneous · 26 weeksAs given in this study (human).
Measurements
Proportion losing >10% body weight
45%
semaglutide
Source sentences
Summary
45% lost >10% body weight.
2 context sentences(design, population, supporting numbers)
Summary · context
This single-centre, randomised, open-label trial enrolled a statistically predetermined sample of 60 adults with HbA1c ≤7.5% (58 mmol/mol) receiving MDI, with a total daily dose (TDD) ≤120 units/day.
Summary · context
Participants were assigned 2:1 to subcutaneous semaglutide 1.0 mg plus insulin degludec, or to continue MDI.
Report a problemFND-3953239808

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Registered trials1

Trials this study reports on, or that list this study as a reference. Registry data from ClinicalTrials.gov.

1 trial · 1 completed · 1 with posted results · source ClinicalTrials.gov (opens in a new tab)

CompletedPhase 4Results postedNCT04538352

Transition From Basal/Bolus to Once-weekly Subcutaneous Semaglutide and Basal Insulin in Patients With T2D

The Cleveland Clinicn = 6018 Jan 2021 to 1 Nov 2023

Type 2 Diabetes

Trial page ClinicalTrials.govUpdated 18 Feb 2025

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
11 Oct 2026, 00:04 UTC
Study results updated
Version 1
9 Oct 2026, 03:06 UTC
First added · source update from Europe PMC

PepBank is a research reference. Talk to a doctor before you use any peptide.

De-intensification of basal-bolus therapy by replacing prandial insulin with once-weekly subcutaneous semaglutide in individuals with well-controlled type 2 diabetes: A single-centre, open-label randomised trial (TRANSITION-T2D).

Summary

Results from this study10

Registered trials1

Transition From Basal/Bolus to Once-weekly Subcutaneous Semaglutide and Basal Insulin in Patients With T2D

Version history

Subjects

Publication types

MeSH terms

Keywords